Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica serovar paratyphi B

Myron M. Levine, Catterine Ferreccio, Robert E Black, Rosanna Lagos, Oriana San Martin, William C. Blackwelder

Research output: Contribution to journalArticle

Abstract

In randomized, controlled field trials in Area Norte and Area Occidente of Santiago, Chile, 2 (Norte) or 3 (Occidente) doses of live oral typhoid vaccine Ty21a in enteric-coated capsules conferred protection against confirmed Salmonella enterica serovar Typhi disease (53% efficacy in Norte; 67% efficacy in Occidente) during 3 years of follow-up. There was also a trend in each trial showing protection against S. enterica serovar Paratyphi B disease (56% efficacy in Norte; 42% efficacy in Occidente). To enhance statistical power, an analysis was performed using pooled data from the 2 trials; this pooling of data was justified by the following facts: epidemiologic surveillance and microbiological methods were identical, the trials overlapped during 22 of the 36 months of follow-up in each trial, the estimates of efficacy against paratyphoid B fever in the 2 trials were roughly similar, and the ratio of follow-up of vaccine recipients to control subjects in both trials was ∼1:1. In the pooled analysis, Ty21a conferred significant protection against paratyphoid B fever (efficacy, 49%; 95% confidence interval, 8%-73%; P = .019).

Original languageEnglish (US)
JournalClinical Infectious Diseases
Volume45
Issue numberSUPPL. 1
DOIs
StatePublished - Jul 15 2007

Fingerprint

Salmonella paratyphi B
Paratyphoid Fever
Typhoid-Paratyphoid Vaccines
Epidemiological Monitoring
Salmonella typhi
Chile
Capsules
Meta-Analysis
Vaccines
Randomized Controlled Trials
Confidence Intervals

ASJC Scopus subject areas

  • Immunology

Cite this

Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica serovar paratyphi B. / Levine, Myron M.; Ferreccio, Catterine; Black, Robert E; Lagos, Rosanna; San Martin, Oriana; Blackwelder, William C.

In: Clinical Infectious Diseases, Vol. 45, No. SUPPL. 1, 15.07.2007.

Research output: Contribution to journalArticle

Levine, Myron M. ; Ferreccio, Catterine ; Black, Robert E ; Lagos, Rosanna ; San Martin, Oriana ; Blackwelder, William C. / Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica serovar paratyphi B. In: Clinical Infectious Diseases. 2007 ; Vol. 45, No. SUPPL. 1.
@article{fcab6797b0e0404fa3ea8be12bd9c7ab,
title = "Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica serovar paratyphi B",
abstract = "In randomized, controlled field trials in Area Norte and Area Occidente of Santiago, Chile, 2 (Norte) or 3 (Occidente) doses of live oral typhoid vaccine Ty21a in enteric-coated capsules conferred protection against confirmed Salmonella enterica serovar Typhi disease (53{\%} efficacy in Norte; 67{\%} efficacy in Occidente) during 3 years of follow-up. There was also a trend in each trial showing protection against S. enterica serovar Paratyphi B disease (56{\%} efficacy in Norte; 42{\%} efficacy in Occidente). To enhance statistical power, an analysis was performed using pooled data from the 2 trials; this pooling of data was justified by the following facts: epidemiologic surveillance and microbiological methods were identical, the trials overlapped during 22 of the 36 months of follow-up in each trial, the estimates of efficacy against paratyphoid B fever in the 2 trials were roughly similar, and the ratio of follow-up of vaccine recipients to control subjects in both trials was ∼1:1. In the pooled analysis, Ty21a conferred significant protection against paratyphoid B fever (efficacy, 49{\%}; 95{\%} confidence interval, 8{\%}-73{\%}; P = .019).",
author = "Levine, {Myron M.} and Catterine Ferreccio and Black, {Robert E} and Rosanna Lagos and {San Martin}, Oriana and Blackwelder, {William C.}",
year = "2007",
month = "7",
day = "15",
doi = "10.1086/518141",
language = "English (US)",
volume = "45",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica serovar paratyphi B

AU - Levine, Myron M.

AU - Ferreccio, Catterine

AU - Black, Robert E

AU - Lagos, Rosanna

AU - San Martin, Oriana

AU - Blackwelder, William C.

PY - 2007/7/15

Y1 - 2007/7/15

N2 - In randomized, controlled field trials in Area Norte and Area Occidente of Santiago, Chile, 2 (Norte) or 3 (Occidente) doses of live oral typhoid vaccine Ty21a in enteric-coated capsules conferred protection against confirmed Salmonella enterica serovar Typhi disease (53% efficacy in Norte; 67% efficacy in Occidente) during 3 years of follow-up. There was also a trend in each trial showing protection against S. enterica serovar Paratyphi B disease (56% efficacy in Norte; 42% efficacy in Occidente). To enhance statistical power, an analysis was performed using pooled data from the 2 trials; this pooling of data was justified by the following facts: epidemiologic surveillance and microbiological methods were identical, the trials overlapped during 22 of the 36 months of follow-up in each trial, the estimates of efficacy against paratyphoid B fever in the 2 trials were roughly similar, and the ratio of follow-up of vaccine recipients to control subjects in both trials was ∼1:1. In the pooled analysis, Ty21a conferred significant protection against paratyphoid B fever (efficacy, 49%; 95% confidence interval, 8%-73%; P = .019).

AB - In randomized, controlled field trials in Area Norte and Area Occidente of Santiago, Chile, 2 (Norte) or 3 (Occidente) doses of live oral typhoid vaccine Ty21a in enteric-coated capsules conferred protection against confirmed Salmonella enterica serovar Typhi disease (53% efficacy in Norte; 67% efficacy in Occidente) during 3 years of follow-up. There was also a trend in each trial showing protection against S. enterica serovar Paratyphi B disease (56% efficacy in Norte; 42% efficacy in Occidente). To enhance statistical power, an analysis was performed using pooled data from the 2 trials; this pooling of data was justified by the following facts: epidemiologic surveillance and microbiological methods were identical, the trials overlapped during 22 of the 36 months of follow-up in each trial, the estimates of efficacy against paratyphoid B fever in the 2 trials were roughly similar, and the ratio of follow-up of vaccine recipients to control subjects in both trials was ∼1:1. In the pooled analysis, Ty21a conferred significant protection against paratyphoid B fever (efficacy, 49%; 95% confidence interval, 8%-73%; P = .019).

UR - http://www.scopus.com/inward/record.url?scp=34447130201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447130201&partnerID=8YFLogxK

U2 - 10.1086/518141

DO - 10.1086/518141

M3 - Article

C2 - 17582564

AN - SCOPUS:34447130201

VL - 45

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 1

ER -